UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Antihyperglycemic drugs that improve cardiovascular outcomes and a model of diabetic cardiomyopathy

Bell, RM; (2019) Antihyperglycemic drugs that improve cardiovascular outcomes and a model of diabetic cardiomyopathy. Heart and Metabolism (80) pp. 18-22. Green open access

[thumbnail of Bell_Cardioprotective diabetic therapies with reviewer comments (RMB).pdf]
Preview
Text
Bell_Cardioprotective diabetic therapies with reviewer comments (RMB).pdf - Accepted Version

Download (351kB) | Preview

Abstract

Recent cardiovascular outcome trials (CVOTs) have transformed the landscape for the management of type 2 diabetes mellitus. In a remarkably short period of time, national and international guidelines have been overhauled to reflect the remarkable cardiovascular benefits of sodium/glucose linked transporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor analogues (GLP-1RA) in mitigating cardiovascular risk. Both SGLT2is and GLP-1RAs remain second-line to metformin, reflecting the historical importance of this biguanide antihyperglycemic. In this review, these three very different antihyperglycemics are discussed in the light of CVOT data and of the preclinical data revealing remarkable pleiotropic signaling effects of these drugs. A model of diabetic cardiomyopathy is discussed, and the points of contact that these therapeutic interventions have upon this model may of help in understanding how each can be best targeted in this complex pathophysiological disease process

Type: Article
Title: Antihyperglycemic drugs that improve cardiovascular outcomes and a model of diabetic cardiomyopathy
Open access status: An open access version is available from UCL Discovery
Publisher version: https://www.heartandmetabolism.com/wp-content/uplo...
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: cardioprotection; diabetic cardiomyopathy; GLP-1 receptor agonist; metformin; SGLT2 inhibitor; type 2 diabetes mellitus
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Pre-clinical and Fundamental Science
URI: https://discovery.ucl.ac.uk/id/eprint/10090163
Downloads since deposit
39Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item